Share-based Payment Arrangement, Expense of GALECTIN THERAPEUTICS INC from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
GALECTIN THERAPEUTICS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • GALECTIN THERAPEUTICS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $498,000, a 3.3% decline year-over-year.
  • GALECTIN THERAPEUTICS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,056,000, a 13% decline year-over-year.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2024 was $2,447,000, a 8.2% increase from 2023.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2023 was $2,261,000, a 21% decline from 2022.
  • GALECTIN THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2022 was $2,867,000, a 38% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

GALECTIN THERAPEUTICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,056,000 $498,000 -$17,000 -3.3% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $2,073,000 $500,000 -$238,000 -32% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $2,311,000 $468,000 -$136,000 -23% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $2,447,000 $590,000 +$93,000 +19% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $2,354,000 $515,000 -$71,000 -12% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $2,425,000 $738,000 +$222,000 +43% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $2,203,000 $604,000 -$58,000 -8.8% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $2,261,000 $497,000 -$184,000 -27% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $2,445,000 $586,000 -$95,000 -14% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,540,000 $516,000 -$131,000 -20% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,671,000 $662,000 -$196,000 -23% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $2,867,000 $681,000 +$27,000 +4.1% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $2,840,000 $681,000 +$94,000 +16% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,746,000 $647,000 +$66,000 +11% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $2,680,000 $858,000 +$604,000 +238% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $2,076,000 $654,000 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $587,000 +$179,000 +44% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $581,000 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $254,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $408,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3

GALECTIN THERAPEUTICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,447,000 +$186,000 +8.2% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $2,261,000 -$606,000 -21% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $2,867,000 +$791,000 +38% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $2,076,000 +$277,000 +15% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $1,799,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.